AxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Conference Call March 14, 2023 8:00 AM ET

Company Participants

Ed Joyce - Director, IR

Karen Zaderej - Chairman, CEO & President

Pete Mariani - EVP & CFO

Conference Call Participants

Mike Sarcone - Jefferies

Chris Pasquale - Nephron

Kyle Rose - Canaccord Genuity

Ryan Zimmerman - BTIG

Ross Osborn - Cantor Fitzgerald

Dave Turkaly - JMP Securities

Operator

Welcome to the AxoGen Fourth Quarter 2022 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Ed Joyce, AxoGen's Director of Investor Relations. Please begin, Mr. Joyce.

Ed Joyce

Thank you, Rob, and good morning, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President; and Pete Mariani, Executive Vice President and Chief Financial Officer. Karen will discuss the quarter and our outlook for the year, and Pete will provide an analysis of our financial performance, followed by a question-and-answer session.

Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen website. Following the end of the live call, a replay will be available on the Investors section of the company's website at www.axogeninc.com.

Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events, including the 2023 financial outlook, timing of the BLA submission and growth trajectory of the company. Forward-looking statements are based on current beliefs and assumptions and are not guarantees of future performance and are subject to risks and uncertainties, including, without limitation, the risks and uncertainties reflected in the company's annual and periodic reports. Actual results or events could differ materially from those described in any forward-looking statement as a result of various factors including, without limitation, the continued impact of COVID-19 on our business, global supply chain issues, record inflation, the impacts of the failure of Silicon Valley Bank and the recent turmoil in the banking industry, hospital staffing issues, product development, product potential, expected clinical enrollment timing and outcomes, regulatory process and approvals, APC renovation, timing and expense, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, global business disruption caused by Russia's invasion of Ukraine and related sanctions as well as those risk factors described under Part 1, Item 1A, Risk Factors of our annual report on Form 10-K for the most recently ended fiscal year.